Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
EDAP EDAP TMS
- 2.860
- +0.230+8.75%
Close Feb 14 16:00 ET
106.12MMarket Cap-4.64P/E (TTM)
2.900High2.655Low90.27KVolume2.660Open2.630Pre Close250.05KTurnover0.30%Turnover RatioLossP/E (Static)37.10MShares8.50052wk High2.38P/B85.21MFloat Cap2.00052wk Low--Dividend TTM29.79MShs Float21.640Historical High--Div YieldTTM9.32%Amplitude0.500Historical Low2.770Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
EDAP TMS Stock Forum
Cortechs.ai and EDAP Announce World's First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center
Thursday, 6th February at 8:00 am
First Focal One® procedure utilizing Cortechs.ai's advanced MRI-imaging technology, OnQ Prostate, successfully performed at the University of California, San Francisco Prostate Cancer Center
OnQ Prostate's Restriction Spectrum Imaging (RSI) technology improves lesion localization and targeting for urologists...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology
Wednesday, 8th January at 7:00 am
AUSTIN, Texas, January 8, 2025 - EDAP TMS SA (NASDAQ: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored by the Centre Léon Bérard, Lyon, France, evaluating proprietary High Intensity Focused Ultrasound (HIFU) technology for the treatment of panc...
Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer
EDAP TMS SA (Nasdaq: EDAP) announced the publication of the HIFI study results in European Urology, comparing Focal One® Robotic HIFU to radical prostatectomy (RP) for localized prostate cancer treatment. The landmark study, involving 3,328 patients across 46 centers, demonstrated that Focal One Robotic HIFU is non-inferior ...
EDAP and Avenda Health Launch World’s First AI-Assisted Focal One® Robotic HIFU Procedures
EDAP TMS SA (Nasdaq: EDAP) and Avenda Health have launched the world's first AI-assisted Focal One® Robotic HIFU procedures for prostate cancer treatment. The collaboration integrates Avenda's FDA-cleared Unfold AI® technology with EDAP's Focal One robotic HIFU platform. Unfold AI creates 3D patient-specific cancer maps, enabling more precise tumor targeting and healthy tissue prese...
EDAP Announces Interim Results from Phase 3 Study Evaluating Robotic HIFU for the Treatment of Deep Infiltrating Endometriosis
EDAP TMS SA (Nasdaq: EDAP) announced interim results from its Phase 3 study evaluating robotic High-Intensity Focused Ultrasound (HIFU) therapy for deep infiltrating endometriosis.
The study, involving 60 patients, aimed to assess acute pelvic pain levels. Key findings include:
1. Robotic HIFU therapy maintained an excellent safety profile, confi...
In reaction to earnings/guidance:
• $CalAmp (CAMP.US)$ +0.6%
Other news:
• $Cano Health (CANO.US)$ +6.1% ( $Humana (HUM.US)$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics (CORT.US)$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial (LPLA.US)$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona (XRAY.US)$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +2.9% (tr...
No comment yet